Express News | Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(C)(4)

ReutersJul 5 08:00 ET

Taysha Gene Therapies Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

DALLAS, July 05, 2024 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies fo

Taysha Gene TherapiesJul 5 00:00 ET

Board Observer of Taysha Gene Therapies Picks Up 5.7% More Stock

Those following along with Taysha Gene Therapies, Inc. (NASDAQ:TSHA) will no doubt be intrigued by the recent purchase of shares by Paul Manning, Board Observer of the company, who spent a stonking US

Simply Wall StJul 4 07:43 ET

Insider Buyers At Taysha Gene Therapies Sitting On US$24m Profit

Yahoo FinanceJul 1 09:59 ET

Taysha Gene Therapies Insider Bought Shares Worth $2,999,999, According to a Recent SEC Filing

Paul B Manning, 10% Owner, on June 27, 2024, executed a purchase for 1,333,333 shares in Taysha Gene Therapies (TSHA) for $2,999,999. Following the Form 4 filing with the SEC, Manning has control over

MT NewswiresJul 1 08:59 ET

Piper Sandler Maintains Taysha Gene Therapies(TSHA.US) With Buy Rating, Cuts Target Price to $7

Piper Sandler analyst Christopher Raymond maintains $Taysha Gene Therapies(TSHA.US)$ with a buy rating, and adjusts the target price from $9 to $7.According to TipRanks data, the analyst has a success

Moomoo NewsJul 1 07:33 ET · Ratings